Resveratrol analog, triacetylresveratrol, a potential immunomodulator of lung adenocarcinoma immunotherapy combination therapies

• DOI: 10.3389/fonc.2022.1007653
• Publication Date: 2023-02-09T05:59:51Z
• Authors: Jian He; Nianxiang Qiu; Xianchao Zhou; Mei Meng; Zixue Liu; Jingquan Li; Shiyu Du; Zhiqiang Sun; Hui Wang
• Keywords: SIRT2; Sirtuin 1

Resveratrol, an activator for longevity regulatory genes-sirtuin family (SIRTs) and Sirtuin 2 (SIRT2) is important factor of SIRTs which demonstrated biological function in cancers, but the underlying mechanism unrevealed.We investigated mRNA protein levels SIRT2 a variety cancers potential role clinical prognosis, as well analysed association between gene immune infiltration various cancers. And analysis two types lung cancer was conducted to construct systematic prognostic landscape. Finally, putative binding site triacetylresveratrol bound built from homology modeling.We concluded that higher affected prognosis especially LUAD cohorts. In addition, linked with better overall survival (OS) patients. Further research suggested possible explanation this phenotype might be are positively correlated infiltrating status multiple immunocytes LU-AD not LUSC, i.e. expression may contribute recruitment CD8+T cell, CD4+ T cell memory resting, Tregs, NK PD-1, also excluding neutrophil, CD8+ naïve B plasma cells LUAD. We found triacetyl-resveratrol most potent agonist efficiency EC 50 low 142.79 nM. As result, appears promising novel biomarker prediction patients immunomodulator anti-PD-1 based immunotherapy combination therapies.